- Trials with a EudraCT protocol (25)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
25 result(s) found for: Glucocorticoid receptor.
Displaying page 1 of 2.
EudraCT Number: 2012-003504-12 | Sponsor Protocol Number: GK_nilani_2012 | Start Date*: 2012-10-05 |
Sponsor Name:Medical Research Laboratory, Clinical institute of Medicine, Aarhus University Hospital | ||
Full Title: Glucocorticoid-induced inhibition of IGF-I activity: exploration of underlying mechanisms. | ||
Medical condition: The catabolic effects induced by long-term glucocorticoid treatment. | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000155-14 | Sponsor Protocol Number: V2.0 | Start Date*: 2013-12-13 |
Sponsor Name:Med. Universität Wien, Universitätsklinik für Innere Medizin II | ||
Full Title: In vivo assessment of the molecular mechanism of inhaled combination of beclomethasone and formoterol on cell differentiation factors and airway remodelling in COPD | ||
Medical condition: COPD | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-007604-15 | Sponsor Protocol Number: STH14971 | Start Date*: 2009-03-03 | |||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | |||||||||||||
Full Title: A Pilot Study of the Effect of Glucocorticoid Receptor Antagonism in Patients with Sub-Clinical Cushing's Syndrome | |||||||||||||
Medical condition: Sub Clinical Cushing's Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004381-19 | Sponsor Protocol Number: NBI-74788-CAH2006 | Start Date*: 2021-06-07 | |||||||||||
Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by O... | |||||||||||||
Medical condition: Classic Congenital Adrenal Hyperplasia (CAH) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023849-30 | Sponsor Protocol Number: CSCAbrein&cognitie1-04 | Start Date*: Information not available in EudraCT |
Sponsor Name:University of Amsterdam | ||
Full Title: The effects of MR and GR blockade on the reconsolidation and extinction of fear memories | ||
Medical condition: Fear conditioning acquisition, reconsolidation and extinction in healthy male subjects. | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004873-17 | Sponsor Protocol Number: NBI-74788-CAH3003 | Start Date*: 2020-10-15 | |||||||||||
Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-... | |||||||||||||
Medical condition: Classic Congenital Adrenal Hyperplasia (CAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024659-10 | Sponsor Protocol Number: 2010-024659-10 | Start Date*: 2011-08-03 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: Can stimulation of the nNOS system in muscle disease with nNOS insufficiency improve heart and skeletal muscle function and cognition? | |||||||||||||
Medical condition: Muscular dystrophy with nNOS insufficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000899-33 | Sponsor Protocol Number: rescue RTX | Start Date*: 2011-08-09 |
Sponsor Name:Department of Endocrinology, Sahlgrenska University Hospital | ||
Full Title: Rituximab (RTX) therapy in steroid resistant patients or patients relapsing after intravenous steroids with active TAO Rescue RTX | ||
Medical condition: Thyroid associated opthalmopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-015837-55 | Sponsor Protocol Number: RAA09-004 | Start Date*: 2010-08-17 | |||||||||||
Sponsor Name:Kings College London [...] | |||||||||||||
Full Title: Double-blind, 36 month, placebo-controlled trial of mifepristone on cognition in alcoholics | |||||||||||||
Medical condition: Alcoholism | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002172-40 | Sponsor Protocol Number: ISIS426115-CS2 | Start Date*: 2014-01-08 | |||||||||||
Sponsor Name:Isis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 426115 (an Antisense Glucocorticoid Receptor Antagonist) Administered Subcutane... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002214-31 | Sponsor Protocol Number: XmAb5871-06 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Xencor, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XmAb®5871 in Patients with IgG4-Related Disease (INDIGO) | |||||||||||||
Medical condition: IgG4-Related Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) BE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000962-14 | Sponsor Protocol Number: CCM-RNT-202101 | Start Date*: 2021-07-02 | |||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus | |||||||||||||
Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002816-25 | Sponsor Protocol Number: MC/PR/033004/002/06 | Start Date*: 2007-09-18 | |||||||||||
Sponsor Name:CHIESI | |||||||||||||
Full Title: Multicentre, multinational, randomised, double blind, double dummy, active drug controlled, parallel group study design clinical trial of the efficacy and tolerability of beclomethasone dipropionat... | |||||||||||||
Medical condition: adult patients with uncontrolled asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002084-27 | Sponsor Protocol Number: cro-725 | Start Date*: 2007-10-02 | |||||||||||
Sponsor Name:Imperial College | |||||||||||||
Full Title: The pharmacokinetics and anti-inflammatory effects of prednisolone in severe asthma. | |||||||||||||
Medical condition: This study is designed to look why patients with severe asthma fail to respond to oral corticosteroids in the same way as patients with non-severe disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004823-66 | Sponsor Protocol Number: ELTCAN1 | Start Date*: 2019-04-17 | |||||||||||
Sponsor Name:Radboudumc | |||||||||||||
Full Title: Early-life stress, the endocannabinoid system, and fear memory extinction | |||||||||||||
Medical condition: healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005244-95 | Sponsor Protocol Number: ALA116402 | Start Date*: 2012-06-27 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | |||||||||||||
Full Title: A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003096-35 | Sponsor Protocol Number: CORT125134-455 | Start Date*: 2019-06-19 | |||||||||||
Sponsor Name:Corcept Therapeutics Incorporated | |||||||||||||
Full Title: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant | |||||||||||||
Medical condition: Endogenous Cushing syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BG (Completed) AT (Completed) PL (Completed) ES (Ongoing) DE (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018289-21 | Sponsor Protocol Number: EndoIGA2010 | Start Date*: 2010-02-25 | |||||||||||||||||||||||||||||||
Sponsor Name:Insitute of Endocrinology | |||||||||||||||||||||||||||||||||
Full Title: Clinical, laboratory and ultrasound markers for the prediction of the response on the pulse-dose treatment by intravenous glucocorticoids in patients with endocrine orbitopathy | |||||||||||||||||||||||||||||||||
Medical condition: active severe endocrine orbitopathy | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002289-33 | Sponsor Protocol Number: 601-0018 | Start Date*: 2023-02-01 | ||||||||||||||||
Sponsor Name:Pulmatrix, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Effect of Dose and Duration of Treatment of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) on S... | ||||||||||||||||||
Medical condition: Allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004956-12 | Sponsor Protocol Number: CORT125134-456 | Start Date*: 2021-02-24 | |||||||||||
Sponsor Name:Corcept Therapeutics Incorporated | |||||||||||||
Full Title: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-... | |||||||||||||
Medical condition: Hypercortisolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) BG (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
